MacroGenics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MGNX research report →
About the company
MacroGenics, Inc. , a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials.
- CEO
- Eric Risser
- IPO
- 2013
- Employees
- 300
- HQ
- Rockville, MD, US
Price Chart
- Market Cap
- $275.23M
- P/E
- -3.94
- P/S
- 1.75
- P/B
- 12.96
- EV/EBITDA
- -4.84
- Div Yield
- 0.00%
- Gross Margin
- 69.93%
- Op Margin
- -40.53%
- Net Margin
- -44.79%
- ROE
- -147.80%
- ROIC
- -49.59%
- Revenue
- $149.50M · 0.78%
- Net Income
- $-74,620,000 · -11.43%
- EPS
- $-1.18 · -10.28%
- Op Income
- $-72,841,000
- FCF YoY
- -15.09%
- 52W High
- $5.08
- 52W Low
- $1.29
- 50D MA
- $4.07
- 200D MA
- $2.54
- Beta
- 1.18
- Avg Volume
- 1.13M
Get TickerSpark's AI analysis on MGNX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 19, 26 | O'Brien Federica F. | other | 22,000 |
| May 18, 26 | O'Brien Federica F. | other | 3,750 |
| May 19, 26 | O'Brien Federica F. | other | 3,750 |
| May 18, 26 | O'Brien Federica F. | other | 3,750 |
| May 19, 26 | Jackson Scott Thomas | other | 22,000 |
| May 18, 26 | Jackson Scott Thomas | other | 3,750 |
| May 19, 26 | Jackson Scott Thomas | other | 3,750 |
| May 18, 26 | Jackson Scott Thomas | other | 3,750 |
| May 18, 26 | HEIDEN WILLIAM K | other | 3,750 |
| May 19, 26 | HEIDEN WILLIAM K | other | 22,000 |
Our MGNX coverage
Recent articles, reports, and earnings notes.
Want a deeper read on MGNX?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Similar companies
Peers in the same neighborhood.